News Release Details

Easy Experience Enables Consumers to Purchase Popular Labcorp Tests Online and Take the Test at Home or at 2,000 Labcorp Patient Service Centers Nationwide

With Ovia Health, OnDemand Expands Labcorp’s Offerings in Digital Health Content and Testing

BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 4, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of Labcorp OnDemand, an easy experience where individuals can purchase Labcorp OnDemand tests online, collect samples in the convenience of their home, or schedule test appointments at one of Labcorp’s 2,000 patient service centers (PSCs), including Labcorp at Walgreens locations. The OnDemand platform includes a suite of the company’s most popular tests, including its wellness, allergy, COVID-19, women’s health and fertility tests, to help individuals manage their health and make more informed decisions. A full list of tests available can be found by visiting www.OnDemand.Labcorp.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220204005229/en/

“Labcorp OnDemand makes it easier for individuals to access our leading diagnostic tests online. The OnDemand platform is an intuitive experience where individuals can purchase tests online and choose from multiple options to take the test, including in the comfort of their own home,” said Amy Summy, Labcorp’s executive vice president and chief marketing officer. “The platform, in addition to our leading Ovia Health digital apps, offers consumers market-leading solutions, backed by over 50 years of science and innovation, to make confident health decisions.”

Labcorp OnDemand includes offerings aimed at improving the health and wellness of millions of people. Labcorp OnDemand’s comprehensive wellness test arms individuals with the information they need to manage their health. Women looking for insights into family planning can tap into offerings that support their fertility journey, including vitamin B12 and folate tests, ovarian reserve tests and quantitative hCG pregnancy tests. Additionally, Labcorp’s leading Pixel by Labcorp COVID-19 PCR and combined COVID-19 + flu at-home collection kits are available through Labcorp OnDemand and continue to be available at zero upfront out-of-pocket costs for those who meet clinical guidelines.

The company expects to make additional Labcorp OnDemand test kit options available through physicians, health plans and employers using their existing ordering channels later this year.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to future prospects for the Labcorp OnDemand platform and its anticipated benefits for customers.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company’s control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company’s ability to implement the company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the company’s filings with the SEC including the information in the company’s most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220204005229/en/

Media: Michele Mazur – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

Source: Labcorp